Why Correct Storage Is a Clinical Governance Issue
Dermal fillers sold in the United Kingdom are regulated as medical devices under the Medical Devices Regulations 2002 (as amended). That regulatory status carries an implicit expectation: practitioners who purchase, store and use these products are responsible for maintaining them in the condition the manufacturer intended from the point of delivery onward. Correct dermal filler storage temperature management is not a minor operational detail; it is part of the chain of custody that underpins product safety and patient welfare.
This article sets out the principles a credible clinic is expected to follow. For any specific product, the manufacturer's Summary of Product Characteristics (SPC) is the definitive authority and should be consulted directly.
Temperature and Light Requirements
Hyaluronic acid (HA) based dermal fillers are sensitive to temperature extremes. Freezing can disrupt the cross-linked gel matrix, altering viscosity and potentially affecting product performance. Excessive heat accelerates degradation. Most HA filler SPCs specify a storage range in the region of 2 degrees C to 25 degrees C; some products have tighter tolerances, particularly those that are lyophilised or contain additional bioactive components. The product label and SPC for each individual product should be treated as the source of truth.
Light exposure, particularly ultraviolet light, can degrade some formulations over time. Products should be stored in their original packaging, in a cool, dry area away from direct sunlight or strong artificial light sources. A dedicated, lockable storage cabinet in a temperature-stable part of the clinic is preferable to open shelving near windows or radiators.
Clinics operating in premises without reliable temperature control should use calibrated refrigeration units with continuous temperature logging. Domestic refrigerators are not suitable because door temperatures fluctuate with use and thermostat accuracy is rarely verified to medical-grade standards.
Maintaining a Sound Filler Cold Chain
The filler cold chain begins at the manufacturer's facility and must remain intact until the product is administered. When sourcing from a supplier, practitioners should ask for confirmation of cold chain compliance during transit. Reputable medical aesthetic suppliers will be able to provide documentation showing that products have been stored and transported within the required temperature range throughout the distribution process.
On receipt of a delivery, the following steps represent sound clinical practice.
- Inspect outer packaging for damage, moisture or signs of temperature excursion.
- Check that ice packs or temperature indicators (where included) are consistent with an unbroken cold chain.
- Transfer temperature-sensitive products to appropriate storage immediately, within the same session if possible.
- Record the delivery date and condition in the clinic stock log.
Any delivery that shows evidence of a potential temperature breach should be quarantined and the supplier contacted before the products are placed into usable stock. Using product that has experienced an unverified temperature excursion exposes patients to a risk that cannot be quantified and exposes the clinic to professional and regulatory liability.
Stock Rotation and Expiry Dating
Stock rotation using a first-in, first-out (FIFO) principle is the standard approach in any clinical environment where perishable medical products are held. Newer deliveries should be placed behind existing stock so that products with earlier expiry dates are used first. This prevents the accumulation of short-dated stock and the temptation to use products close to or past expiry in a hurry.
Expiry dates should be verified at three points: on receipt, when moved to the clinical area, and immediately before use. If a product is found to be expired at any of these checks, it must be removed from usable stock promptly. Expired medical devices should not be used; this is not a judgement call. Disposal must follow local clinical waste regulations.
Clinics should conduct a regular stock audit, at minimum monthly, to identify slow-moving product and adjust ordering volumes accordingly. Holding excess inventory increases the risk of expiry waste and ties up capital unnecessarily.
Batch Traceability and Record-Keeping
Filler batch traceability is a regulatory and professional requirement, not an optional administrative exercise. Every product used on a patient should be documented in the patient's clinical record with the product name, manufacturer, batch number and expiry date. This information enables the clinic to act swiftly and precisely in the event of an MHRA product recall or a manufacturer-initiated field safety corrective action.
The MHRA's Yellow Card scheme allows healthcare professionals and patients to report suspected adverse reactions and device incidents. Accurate batch records are essential to making a meaningful report. Without them, a clinic cannot contribute usefully to post-market surveillance, which is the mechanism by which safety signals are identified across the population.
From an indemnity perspective, detailed batch records demonstrate that the practitioner exercised reasonable care. Professional indemnity insurers consistently advise that contemporaneous clinical records, including product batch details, are among the most important protections available. NHS guidance suggests a minimum retention period of eight years for adult records; independent aesthetic clinics should take legal advice on the appropriate period for their practice structure.
Aseptic and Infection-Prevention Principles
Aseptic technique in the handling of injectable products is a foundational requirement, consistent with guidance from the Royal College of Nursing and Health Education England on safe injection practice. Pre-filled syringes should remain sealed in their sterile packaging until immediately before use, and packaging integrity should be visually inspected before opening. Gloves must be worn. Products should never be pooled, decanted or reused across patients; multi-patient use of a single syringe carries a significant cross-contamination risk and is not acceptable practice.
Work surfaces should be decontaminated before product handling. These are not extraordinary precautions; they are the baseline expected of any practitioner working with injectable medical devices.
The Clinic as the Last Line of Quality Assurance
Manufacturers and suppliers have quality obligations that extend to the point of delivery. Beyond that point, the clinic assumes responsibility. Maintaining correct dermal filler storage temperature, preserving the cold chain, rotating stock diligently, recording batch and expiry details, and handling products aseptically collectively define the standard a patient can reasonably expect. Meeting that standard is the foundation of any credible clinical governance framework.
Frequently Asked Questions
What is the recommended storage temperature for hyaluronic acid dermal fillers?
Most hyaluronic acid based dermal fillers should be stored between 2 degrees C and 25 degrees C, away from direct light and freezing conditions. The precise range for any given product is stated in its Summary of Product Characteristics (SPC), which manufacturers are required to publish. Clinicians should always defer to the product-specific SPC rather than a general rule.
What does 'cold chain' mean in the context of aesthetic injectables?
Cold chain refers to the uninterrupted temperature-controlled sequence from the point of manufacture through distribution, storage and point of use. A break anywhere in this chain can degrade product quality and may invalidate the manufacturer's guarantee of safety and efficacy. For aesthetic injectables, this means verifying that suppliers maintain cold chain documentation and that clinic storage conditions are monitored continuously.
Why does batch traceability matter for dermal fillers?
Batch traceability allows a clinic to identify and respond promptly if a product recall is issued by the manufacturer or the MHRA. It also forms part of the clinical record that demonstrates appropriate due diligence if a patient query or adverse event arises later. The MHRA's Yellow Card scheme and the manufacturer's own pharmacovigilance obligations depend on practitioners being able to report product details accurately.
How should dermal filler expiry dates be managed in a busy clinic?
A first-in, first-out (FIFO) rotation system ensures that older stock is used before newer deliveries. Expiry dates should be checked at the point of delivery, again when stock is placed in the clinical area, and once more immediately before use. Any product approaching expiry that is unlikely to be used should be quarantined and disposed of in line with local clinical waste protocols, not used in a hurry.
What are the key aseptic principles for handling pre-filled syringes?
Pre-filled syringes should remain in their sterile packaging until the moment of use, and packaging integrity should be visually inspected before opening. The external surface of the syringe should not be touched by ungloved hands. Any product drawn into a secondary container or that has had its needle changed should be treated with the same aseptic precautions as any other injectable preparation. These principles align with guidance from the Royal College of Nursing and Health Education England on injection safety.